IV-361 structure
|
Common Name | IV-361 | ||
---|---|---|---|---|
CAS Number | 2055741-39-2 | Molecular Weight | 457.62 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C23H32FN5O2Si | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of IV-361IV-361 is an orally active and selective CDK7 inhibitor (Ki≤50 nM). IV-361 has anti-cancer activity (US20190256531A1)[1]. |
Name | IV-361 |
---|
Description | IV-361 is an orally active and selective CDK7 inhibitor (Ki≤50 nM). IV-361 has anti-cancer activity (US20190256531A1)[1]. |
---|---|
Related Catalog | |
Target |
CDK7:≤50 nM (Ki) CDK2:≥1000 nM (Ki) |
In Vitro | IV-361 has less inhibition on CDK2 (Ki≥1000 nM) or PLK1 (Ki≥5000 nM)[1]. IV-361 exhibits excellent IL-2 and IL-17 production inhibitory activity (all IC50≤100 nM) in periphery blood mononuclear cell (PBMC)[1]. IV-361 exhibits excellent HCT-116 cell growth inhibitory activity (GI50≤100 nM)[1]. |
In Vivo | IV-361 (25 mg/kg/day; orally) exhibits 46% or more rate of suppression of tumor volume in female BALB nude mice with HCT-116[1]. |
References |
[1]. Noriaki Iwase, et al. Substituted dihydropyrrolopyrazole derivative. US20190256531A1. |
Molecular Formula | C23H32FN5O2Si |
---|---|
Molecular Weight | 457.62 |